Henry Schein (NASDAQ:HSIC) Director William Daniel Buys 10,000 Shares

Henry Schein, Inc. (NASDAQ:HSIC) Director William Daniel bought 10,000 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was bought at an average cost of $69.19 per share, with a total value of $691,900.00. Following the completion of the transaction, the director owned 20,000 shares in the company, valued at approximately $1,383,800. This trade represents a 100.00% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Henry Schein Trading Up 0.5%

Shares of NASDAQ:HSIC traded up $0.36 on Tuesday, hitting $69.35. The company had a trading volume of 1,658,628 shares, compared to its average volume of 1,364,425. The firm’s 50-day simple moving average is $75.59 and its two-hundred day simple moving average is $75.13. Henry Schein, Inc. has a 1 year low of $61.94 and a 1 year high of $89.29. The company has a quick ratio of 0.75, a current ratio of 1.36 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $7.90 billion, a price-to-earnings ratio of 20.95, a P/E/G ratio of 1.78 and a beta of 0.82.

Henry Schein (NASDAQ:HSIC) last posted its earnings results on Tuesday, May 5th. The company reported $1.32 EPS for the quarter, topping the consensus estimate of $1.20 by $0.12. The firm had revenue of $3.37 billion during the quarter, compared to analysts’ expectations of $3.34 billion. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. The company’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same period last year, the company posted $1.15 EPS. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Equities analysts anticipate that Henry Schein, Inc. will post 5.31 earnings per share for the current fiscal year.

Institutional Trading of Henry Schein

A number of institutional investors and hedge funds have recently bought and sold shares of the company. CYBER HORNET ETFs LLC bought a new stake in shares of Henry Schein in the second quarter worth approximately $25,000. MUFG Securities EMEA plc bought a new stake in shares of Henry Schein in the second quarter worth approximately $27,000. Flagship Harbor Advisors LLC bought a new stake in shares of Henry Schein in the fourth quarter worth approximately $30,000. Federated Hermes Inc. bought a new stake in shares of Henry Schein in the fourth quarter worth approximately $32,000. Finally, Los Angeles Capital Management LLC bought a new stake in shares of Henry Schein in the fourth quarter worth approximately $37,000. 96.62% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently issued reports on HSIC shares. JPMorgan Chase & Co. increased their price target on shares of Henry Schein from $78.00 to $92.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Barrington Research set a $97.00 price target on shares of Henry Schein and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Henry Schein in a research note on Monday, May 4th. Leerink Partners reiterated a “market perform” rating on shares of Henry Schein in a research note on Monday, March 9th. Finally, UBS Group reiterated a “neutral” rating and issued a $85.00 price target (down from $87.00) on shares of Henry Schein in a research note on Wednesday, May 6th. Six equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $86.83.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.